| Abstrakt: |
A recent study conducted at the Fred Hutchinson Cancer Research Center in Seattle, Washington, focused on evaluating the safety and efficacy of targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) with autologous T-lymphocytes engineered to express a ROR1 chimeric antigen receptor (CAR) in patients with advanced hematopoietic and epithelial malignancies. The study included 21 patients with ROR1+ tumors, with promising results observed in chronic lymphocytic leukemia (CLL) patients, while limited antitumor activity was seen in patients with triple-negative breast cancer (TNBC) and non-small-cell lung cancer (NSCLC). The research concluded that ROR1 CAR T cells were generally well tolerated, with identified limitations including immunogenicity of the CAR and lack of sustained tumor infiltration. [Extracted from the article] |
